Paying a High Price for Low Costs: Why There Should Be No Legal Constraints on the Profits That Can Be Made on Drugs for Tropical Diseases
Journal of Medical Ethics 2009 May; 35(5): 315-319
This paper deals with the question of how to price drugs for tropical diseases. The thesis defended in the paper is: (i) there should be no legal constraints on the profits pharmaceutical companies can make on their products for tropical diseases. In essence, (i) expresses the idea that drugs for tropical diseases should be treated as any other product on the free market and that the producers of these drugs should be allowed to sell their products at whatever price the market can bear. The main argument in favour of (i) is first outlined. Five common arguments against (i) are thereafter discussed, and it is argued that all of these fail in their intended purpose.
Showing items related by title, author, creator and subject.
Oprea, L.; Braunack-Mayer, A.; Gericke, C.A. (2009-05)Neglected and tropical diseases, pervasive in developing countries, are important contributors to global health inequalities. They remain largely untreated due to lack of effective and affordable treatments. Resource-poor ...
Drug Sales Bring Huge Profits, and Scrutiny, to Cancer Doctors; Insurers and Experts See High Costs and Conflicts Abelson, Reed (2003-01-26)